



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 5/10, 7/01, A61K 48/00</b>		A1	(11) International Publication Number: <b>WO 99/35280</b> (43) International Publication Date: <b>15 July 1999 (15.07.99)</b>
(21) International Application Number: <b>PCT/EP99/00002</b> (22) International Filing Date: <b>3 January 1999 (03.01.99)</b>  (30) Priority Data: 0005/98                    6 January 1998 (06.01.98)                    DK		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): <b>BAVARIAN NORDIC RESEARCH INSTITUTE A/S [DK/DK]; Naverland 2, DK-2600 Glostrup (DK).</b>  (72) Inventors; and (75) Inventors/Applicants (for US only): <b>GÜNZBURG, Walter [AT/AT]; Weyprechtgasse 10, A-2340 Mödling (AT). KLEIN, Dieter [DE/AT]; Mollersdorf 50, A-3430 Tulln (AT). TABOTTA, Walter [AT/AT]; Staudingerstrasse 10/2/14-16, A-1200 Wien (AT). SALMONS, Brian [GB/DE]; Mitterfeldstrasse 11, D-85229 Markt Indersdorf (DE).</b>		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agent: <b>PIELKEN, Petra; Bavarian Nordic Research Institute GmbH, Fraunhoferstrasse 18b, D-82152 Martinsried (DE).</b>			

(54) Title: RECONSTITUTING RETROVIRAL VECTOR (RECON VECTOR) FOR TARGETED GENE EXPRESSION

## (57) Abstract

The present invention relates to a retroviral vector which is especially applicable as a safe gene transfer vehicle for targeted gene therapy. Said retroviral vector comprises one or more promoters inserted in antisense orientation within the 5'LTR region and one or more coding sequences inserted in antisense orientation within the 3'LTR region. Both, the promoter as well as the coding sequence, are additionally inserted in such a way as to ensure that the promoter and the coding sequence become duplicated during the process of reverse transcription in a target cell and thus appear in the 3' as well as in the 5'LTR region of the resulting provirus in a fashion where the promoter is located upstream of the coding sequence allowing it to drive gene expression. This system avoids any leakiness of gene expression in the packaging cells, and allows expression of transferred genes in the target cell without the necessity for external stimuli.

## ReCon Vector



A02

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Reconstituting retroviral vector (ReCon vector) for targeted gene expression

The present invention relates to a new retroviral vector which is especially applicable as a safe gene transfer vehicle for targeted gene therapy. The new vector enables the expression of, e.g., toxic genes, the expression of genes with a specific function that is incompatible with virus vector production and the expression of genes causing vector rearrangements necessary for specific biochemical operations.

10

### Background of the invention

The most efficient and well developed systems for *in vivo* gene therapy are based upon retroviruses because the use of retroviral vectors (RV) is currently the method of choice for the transfer of therapeutic genes in a variety of approved protocols both in the USA and in Europe (Kotani, H., P.B. Newton, S. Zhang, Y.L. Chiang, E. Otto, L. Weaver, R.M. Blaese, W.F. Anderson, and G.J. McGarrity. 1994, Human Gene Therapy 5: 19-28). Retroviruses infect a wide variety of cells and are ideal tools for the stable delivery of genes to cells since the retrovirus is able to integrate the DNA form of its genome into the genome of the target cell. Thus, all daughter cells of an infected cell carry the retroviral vector DNA including the therapeutic gene. However, current efficient transfer of therapeutic genes usually requires that the infection of target cells with the RV carrying the genes occurs *in vitro*, and successfully infected cells are then returned to the affected individual (Rosenberg, S.A., Anderson, W.F., Blaese, R.M. et al. 1992, Hum. Gene Ther. 3: 75-90; Anderson, W.F. 1992. Human gene therapy. Science 256: 808-813). Such *ex vivo* gene therapy protocols are ideal for

20  
15  
20  
25  
30

5 correction of medical conditions in which the target cell population can be easily isolated. Additionally, the *ex vivo* infection of target cells allows the administration of large quantities of concentrated virus which can be rigorously safety tested before use.

10 Unfortunately, only a fraction of the possible applications for gene therapy involve target cells that can be easily isolated, cultured and then reintroduced. Additionally, the complex technology and associated high costs of *ex vivo* gene therapy effectively preclude its disseminated use world-wide. Future facile and cost-effective gene therapy will require an *in vivo* approach in which the RV, or cells producing the recombinant virus, are directly administered to the patient in the form of an injection or 15 simple implantation of RV producing cells.

20 This kind of *in vivo* approach, of course, introduces a variety of new problems. First of all, and above all, safety considerations have to be addressed. Virus will be produced, possibly from an implantation of virus producing cells, and there will be no opportunity to precheck the produced virus. It is important to be aware of the finite risk involved in the use of such systems.

25 To minimize this risk the so-called ProCon vector has been developed as a safe gene transfer vehicle for targeted gene therapy using the principle of promoter conversion typical for retroviruses (PCT/EP95/03445):

30 The retroviral genome consists of an RNA molecule with the structure R-U5-gag-pol-env-U3-R. During the process of reverse transcription, the U5 region is duplicated at the right hand end of the generated DNA molecule,

whilst the U3 region is duplicated and placed at the left hand end of the generated DNA molecule. The resulting structure U3-R-U5 is called LTR (Long Terminal Repeat) and is thus identical and repeated at both ends of the DNA structure or provirus. The U3 region at the left hand end of the provirus harbours the promoter. This promoter drives the synthesis of an RNA transcript initiating at the boundary between the left hand U3 and R regions and terminating at the boundary between the right hand R und U5 region. This RNA is packaged into retroviral particles and transported into the target cell to be infected. In the target cell the RNA genome is again reverse transcribed as described above.

In the ProCon vector the right hand U3 region is altered, but the normal left hand U3 structure is maintained; the vector can be normally transcribed into RNA utilizing the normal retroviral promoter located within the left hand U3 region. However, the generated RNA will only contain the altered right hand U3 structure. In the infected target cell, after reverse transcription, this altered U3 structure will be placed at both ends of the retroviral structure.

The altered region carries a polylinker instead of the U3 region. Thus, any promoter, including those directing tissue specific expression can be easily inserted. This promoter is then utilized exclusively in the target cell for expression of linked genes carried by the retroviral vector. Accordingly, in the packaging cell line the expression of the retroviral vector is regulated by the normal unselective retroviral promoter contained in the U3 region. However, as soon as the vector enters the target cell promoter conversion occurs, and the therapeutic and/or marker genes are expressed from a

5 tissue specific promoter of choice introduced into the polylinker. Not only  
can virtually any tissue specific promoter be included in the system,  
providing for the selective targeting of a wide variety of different cell  
types, but additionally, following the conversion event, the structure and  
properties of the retroviral vector no longer resemble that of a virus. This,  
of course, has extremely important consequences from a safety point of  
view, since other retroviral vectors readily undergo genetic recombination  
10 with the retroviral packaging construct and/or endogenous retroviruses to  
produce potentially pathogenic viruses. Promoter conversion vectors do  
not resemble retroviruses because they no longer carry U3 retroviral  
promoters after conversion thus reducing the possibility of genetic  
recombination.

15 Rather than a tissue specific promoter a regulatable promoter can be  
inserted in the polylinker, allowing the conditional expression of genes  
carried by the retroviral vector.

20 However, all current systems of controlling gene expression are not  
absolute, and all require the additional inconvenience of requiring the  
presence of an inducer or repressor substance or stimulus.

#### Object of the invention

25 It is an object of the present invention to further improve retroviral vectors  
for gene transfer into target cells, especially to provide a system which  
avoids any leakiness of gene expression in the packaging cells and which  
allows expression of transferred genes only in the target cell, preferably  
30 without necessity for external regulator substances or stimuli.

**Abstract of the invention**

- 5 To achieve the foregoing and other objects, the present invention provides a retroviral vector comprising one or more promoters inserted in antisense orientation within the 5' LTR region and one or more coding sequences inserted in antisense orientation within the 3' LTR region, both, the promoter as well as the coding sequence, inserted in such a way as to ensure that the promoter and the coding sequence become duplicated during the process of reverse transcription in a target cell and appear in the 3' as well as in the 5' LTR region of the resulting provirus in a fashion where the promoter is located upstream of the coding sequence allowing it to drive gene expression (see Figure 1).
- 10
- 15 First of all, in the antisense orientation there is no gene following on the left (downstream) of the promoter. Additionally, the gene to be transferred and expressed in the target cell is non-functional because there is no promoter located to the right (upstream) of it.
- 20
- 25 To generate the retroviral particle and the packaged vector, respectively, the principle of a retroviral vector system is used. This system consists of two components: the retroviral vector itself in which the genes encoding the viral proteins have been replaced, and a packaging cell line which provides the modified retrovirus with the missing viral proteins. This packaging cell line has been transfected with one or more plasmids carrying the genes enabling the modified retroviral vector to be packaged, but lacks the ability to produce replication competent viruses.
- 30

After introduction of the vector into the packaging cell line, the retroviral vector is transcribed into RNA. This transcription is regulated by the normal unselective retroviral promoter contained in the U3 region of the 5' LTR (see above) and initiates at the boundary between the U3 and R region and terminates at the boundary between the R and U5 region of the 3' LTR. The RNA which represents the recombinant retroviral genome is packaged by the viral proteins produced by the packaging cell line to form retroviral particles which bud from the cell. These are used to infect the target cell.

After infection of the target cell, the recombinant viral RNA will be reverse transcribed into DNA. During this process the promoter inserted in antisense orientation at the 5' end of the viral RNA will be duplicated and translocated to the 3' end of the generated DNA molecule, whilst the coding sequence(s) from the 3' end of the viral RNA will be duplicated and translocated to the 5' end of the DNA molecule (see Figure 1).

As a result of this process the promoter and the gene are present twice within the target cells. Further, each copy of the gene is now linked to a copy of the promoter located upstream relative to the coding region allowing the gene to be expressed in the target cell. Consequently, this system avoids any leakiness of gene expression in the packaging cells, and allows expression of transferred genes in the target cell without the necessity for external stimuli.

In a preferred embodiment of the invention the promoter is inserted within the U5 region of the 5' LTR, preferably wholly or partly replacing the U5 region. Nevertheless, the promoter can also be inserted between the R and U5 region of the 5' LTR.

5       The gene coding sequences are especially inserted within the U3 region of the 3' LTR, preferably wholly or partly replacing the U3 region. Alternatively, they can be inserted between the R and U3 region of the 3' LTR.

10      In a further preferred embodiment the coding sequences comprise heterologous DNA. The term „heterologous“ is used for any combination of DNA sequences that is not normally found intimately associated in nature.

15      The coding sequences are preferably, but not limited to one or more elements of the group consisting of marker genes, therapeutic genes, antiviral genes, antitumour genes, cytokine genes and/or toxin genes.

20      Said marker and therapeutic genes are preferably selected from one or more elements of the group consisting of  $\beta$ -galactosidase gene, neomycin gene, Herpes Simplex Virus thymidine kinase gene, puromycin gene, cytosine deaminase gene, hygromycin gene, secreted alkaline phosphatase gene, guanine phosphoribosyl transferase (gpt) gene, alcohol dehydrogenase gene, hypoxanthine phosphoribosyl transferase (HPRT) gene, green fluorescent protein (gfp) gene, cytochrome P450 gene and/or toxin genes such as  $\alpha$  subunit of diphtheria, pertussis toxin, tetanus toxoid.

25

Additionally, the retroviral vector may comprise one or more elements regulating expression of the coding sequences.

30

5       The inserted promoter is preferably a strong, constitutive promoter such as  
          that of cytomegalovirus, simian virus 40, Rous Sarcoma Virus, or the  
          ubiquitin C promoter, or in another embodiment a promoter that controls  
          target cell specific expression and may be regulatable by transacting  
          molecules.

10      The target cell specific regulatory elements and promoters are preferably,  
          but not limited to one or more elements of the group consisting of Whey  
          Acidic Protein (WAP), Mouse Mammary Tumour Virus (MMTV),  $\beta$ -  
          lactoglobulin and casein specific regulatory elements and promoters, which  
          may be used to target human mammary tumours, pancreas specific  
          regulatory elements and promoters including carbonic anhydrase II and  $\beta$ -  
          glucokinase regulatory elements and promoters, lymphocyte specific  
          regulatory elements and promoters including human immunodeficiency  
          virus (HIV), immunoglobulin and MMTV lymphocytic specific regulatory  
          elements and promoters and MMTV specific regulatory elements and  
          promoters such as MMTVP2 conferring responsiveness to glucocorticoid  
          hormones or directing expression to the mammary gland, T-cell specific  
          regulatory elements and promoters such as T-cell receptor gene and CD4  
          receptor promoter, B-cell specific regulatory elements and promoters such  
          as immunoglobulin promoter or mb1. Said regulatory elements and  
          promoters regulate preferably the expression of at least one of the coding  
          sequences of said retroviral vector.

25      Furthermore, the retroviral vector is especially replication-defective and  
          preferably based on a vector of the pLXSN family and/or on a promoter  
          conversion vector (see above).

The LTR regions are preferably, but not limited, selected from at least one element of the group consisting of LTR's of Murine Leukaemia Virus (MLV), Mouse Mammary Tumour Virus (MMTV), Murine Sarcoma Virus (MSV), Simian Immunodeficiency Virus (SIV), Human Immunodeficiency Virus (HIV), Human T-cell Leukaemia Virus (HTLV), Feline Immunodeficiency Virus (FIV), Feline Leukaemia Virus (FELV), Bovine Leukaemia Virus (BLV) and Mason-Pfizer-Monkey virus (MPMV).

10

In a further embodiment of the invention a retroviral vector system is provided comprising a retroviral vector as described above as a first component and a packaging cell line harbouring at least one retroviral and/or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged.

15

The packaging cell line harbours retroviral or recombinant retroviral constructs coding for those retroviral proteins which are not encoded in said retroviral vector. The packaging cell line is preferably, but not limited, selected from an element of the group consisting of psi-2, psi-Crypt, psi-AM, GP+E-86, PA317, GP+envAM-12, Fly A13, BOSC 23, BING, Fly RD 18, ProPak-X, -A.52 and -A.6, or of any of these supertransfected with recombinant constructs allowing expression of surface proteins from other enveloped viruses.

20

After introducing the retroviral vector of the invention as described above in a retroviral packaging cell line a retroviral particle is provided comprising the recombinant retroviral genome.

25

30

10

5       The invention includes also a retroviral provirus, mRNA of a retroviral provirus according to the invention, any RNA resulting from a retroviral vector according to the invention and cDNA thereof, as well as host cells infected with a retroviral particle according to the invention.

10      A further embodiment of the invention provides a method for introducing homologous and/or heterologous nucleotide sequences into target cells (as e.g. CRFK, NIH/3T3, T-47D, RAT2, MV 1 LU (NBL-7), T-24, PG13, PA317, A20, HT-1080, PANC-1, MIA PA CA-2, HEP G2, 293, MCF-7, CV-1, COS 1, COS 7, FLY2A1) comprising infecting a target cell population *in vivo* and *in vitro* with recombinant retroviral particles produced by the packaging cell line. The nucleotide sequences are selected from one or more elements of the group consisting of genes or parts of genes encoding for proteins, regulatory sequences and promoters.

15      The retroviral vector, the retroviral vector system and the retroviral provirus as well as RNA thereof is used for producing a pharmaceutical composition for *in vivo* and *in vitro* gene therapy in mammals including humans. Furthermore, they are used for targeted integration in homologous cellular sequences.

#### **Summary of the invention**

25

The invention comprises the following, alone or in combination:

30

A retroviral vector comprising one or more promoters inserted in antisense orientation within the 5' LTR region and one or more coding

5 sequences inserted in antisense orientation within the 3' LTR region, both, the promoter as well as the coding sequence, inserted in such a way as to ensure that the promoter and the coding sequence become duplicated during the process of reverse transcription in a target cell and appear in the 3' as well as in the 5' LTR region of the resulting provirus in a fashion where the promoter is located upstream of the coding sequence allowing it to drive gene expression.

10

the retroviral vector as above, wherein said promoter is inserted within the U5 region of the 5' LTR;

15

the retroviral vector as above, wherein said coding sequence is inserted within the U3 region of the 3' LTR;

20 the retroviral vector as above, wherein said coding sequence comprises heterologous DNA;

25

the retroviral vector as above, wherein said coding sequence is selected from one or more elements of the group consisting of marker genes, therapeutic genes, antiviral genes, antitumour genes, cytokine genes and/or toxin genes;

30

the retroviral vector as above, wherein said promoter is a strong, constitutive promoter;

the retroviral vector as above, wherein said retroviral vector is replication-defective;

30

the retroviral vector as above, wherein said retroviral vector is based on a vector of the pLXSN family;

5

the retroviral vector as above, wherein said retroviral vector is based on a promoter conversion vector;

10

a recombinant retroviral vector system comprising a retroviral vector as above as a first component, and a packaging cell line harbouring at least one retroviral and/or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged;

15

a retroviral particle produced by transfecting a packaging cell line of a retroviral vector system as above with the retroviral vector as above;

a retroviral provirus produced by infection of target cells with a recombinant retroviral particle as above;

20

mRNA of a retroviral provirus as above;

RNA of a retroviral vector as above;

a host cell infected with a retroviral particle as above;

25

a pharmaceutical composition containing a therapeutically effective amount of a recombinant retroviral particle as above and/or a recombinant retroviral vector system as above;

a method for introducing homologous and/or heterologous nucleotide sequences into target cells comprising infecting the target cells with  
5 recombinant retroviral particles as above;

use of a recombinant retroviral vector as above and/or of a recombinant retroviral vector system as above and/or of a retroviral particle as above for producing a pharmaceutical composition for gene therapy.

10

### Examples

The following examples will further illustrate the present invention. It will be well understood by a person skilled in the art that the provided  
15 examples in no way may be interpreted in a way that limits the applicability of the technology provided by the present invention to this examples.

20 **I. Construction of a ProCon based expression vector with an elongated packaging signal**

The ProCon based expression vector (see PCT Application No. PCT/EP95/03445) pLX125 was constructed by ligation of the fragment containing the MLV-5'LTR as well as the elongated packaging signal of  
25 pLXSN (Miller and Rosman (1989) Biotechniques 7: 980-990) with the fragment containing the neomycin gene under the control of the SV40 promoter and the MMTV-3'LTR of a vector designated p125.6 (see also PCT Application No. PCT/EP95/03445).

30

The vector pLXSN was digested with the restriction enzymes AflIII and BamHI resulting in a 3545 bp fragment, and p125.6 was digested with the restriction enzymes AflII and BamHI resulting in a 4263 bp fragment. The DNA fragments of both digests were purified by running on a 0.8% agarose gel, the DNA bands were excised and DNA eluted using the Qiaquick protocol (Qiagen). After ethanol precipitation the DNA fragments were resuspended in water.

10

40 ng of the 3545 bp AflIII/BamHI fragment from vector pLXSN and 100 ng of the 4263 bp AflII/BamHI fragment from vector p125.6 were mixed and ligated at room temperature for 1 h using T4 ligase (Boehringer). Nucleotides were filled in using the Klenow enzyme for 12 h at 12°C followed by a ligation of the blunt ends at 14°C for 14 h using the T4 ligase (Boehringer). The enzymes were inactivated at 65°C for 20 min. The DNA was butanol precipitated with a 10 fold volume of butanol and resuspended in water and electroporated into DH10B bacteria (Gibco). Ampicillin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes EcoRI, AflII, StuI, BssHII and KpnI. The final correct ProCon vector was designated pLX125.

15

20

## II. Construction of the ProCon based expression vector pLXPCMTV

25

The ProCon expression vector pLXPCMTV - containing only one single SacII restriction site - was constructed by removing the SacII restriction site upstream the 5'LTR in the expression vector pLX125 by partial restriction digest. pLX125 was partially digested with the restriction enzyme SacII and heat inactivated for 20 min at 65°C. For blunt end ligation the nucleotide

30

ends were cut off with T4 polymerase (New England BioLabs) for 20 min at 12°C. The DNA was purified by running on a 0.8% agarose gel, the 7810 bp fragment DNA band was excised and DNA eluted using the Qiaquick protocol (Qiagen). After ethanol precipitation the DNA was resuspended in water. 10 ng of the DNA fragment was ligated for 12 h at 4°C using T4-ligase (Boehringer). The ligase was inactivated at 65°C for 20 min and the DNA butanol precipitated with a 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into DH10B bacteria (Gibco). Ampicillin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes MluI and SacII and sequenced. The final correct plasmid was designated pLXPCMTV.

15           **III. Construction of an *egfp* expressing ProCon vector**

As a control vector for the ReCon system the ProCon expression vector pLXPCEGFP (= pLESNm1P) was constructed by ligation of the fragment containing the *egfp* gene obtained from plasmid pEGFP-1 (Clontech) with the pLXPCMTV backbone.

The pLXPCMTV backbone was digested with the restriction enzyme HpaI yielding a 7800 bp fragment. For isolation of the *egfp* gene the plasmid pEGFP was digested with the restriction enzymes HpaI and SmaI yielding a 860 bp fragment. The digestion mixtures were purified on a 0.8% agarose gel. The 7800 bp and the 860 bp fragment were excised and the DNA eluted using the Qiaex protocol (Qiagen).

40 ng of the pLXPCMTV backbone and 50 ng of the HpaI/SmaI fragment were mixed and ligated for 14 hours at 16°C using T4 ligase (Promega). The ligase was inactivated at 65°C for 20 min and the DNA butanol precipitated with 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into DH10B bacteria (Gibco). Ampicillin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes KpnI, SpeI or BamHI/XhoI and sequenced. The final correct plasmid was designated pLXPCEGFP (= pLESNm1P).

#### IV. Construction of an expression vector containing the inverse *egfp* gene within the 3'LTR region

The expression vector pLXPCEGFP.r was constructed by ligation of the fragment containing the *egfp* gene obtained from plasmid pEGFP-1 (Clontech) with the ProCon based pLXPCMTV backbone as described above (see item II).

The pLXPCMTV backbone was digested with the restriction enzymes MluI and SacII yielding a 6599 bp fragment with the eliminated MMTV U3 region.

The *egfp.pA* gene including the polyA site was isolated from the plasmid pEGFP-1 using the PCR method. The left hand primer (5'-ATAGTAACGCGTGGTCGCCACCATGGTGAG-3') was specific to the beginning of the *egfp* gene also creating a new MluI restriction site (underlined), and the right hand primer (5'-GCGATCCGCGGTGGACAAACCACAACTAGA-3') was specific to the end

of the *egfp* gene also creating a new SacII restriction site (underlined). PCR resulted in a 978 bp fragment. The fragment was purified by running on a 5 0.8% agarose gel, the DNA band was excised and DNA eluted using the Qiaquick protocol (Qiagen). The *egfp* fragment was digested with the restriction enzymes MluI and SacII and the digestion mixture was purified on a 0.8% agarose gel, the DNA band was excised and DNA eluted using the Qiaex protocol (Qiagen).

10

320 ng of the pLXPCMTV backbone and 80 ng of the MluI/SacII fragment were mixed and ligated for 14 h at 16°C using T4 ligase (New England BioLabs). The ligase was inactivated at 65°C for 20 min and the DNA butanol precipitated with 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into DH10B bacteria (Gibco). 15 Ampicillin/Kanamycin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes HpaI and sequenced. The final correct plasmid was designated pLXPCEGFP.r.

20

#### V. ReCon expression vector pRC1UbpshEGFP

##### 1. Construction of the ReCon expression vector pRC1UbpshEGFP containing the inverse *egfp* gene within the 3'LTR and the inverse ubiquitin promoter within the 5'LTR

25

The ReCon expression vector pRC1UbpshEGFP was constructed by ligation of the fragment containing the ubiquitin promoter obtained from plasmid pTEJ-8 (Johansen et al. (1990) FEBS Lett. 267: 289-294) with the pLXPCEGFP.r backbone. For this purpose the ubiquitin promoter had to be first 30 subcloned.

5 For subcloning the ubiquitin promoter the vector pLPCMTV had to be generated from pLXPCMTV by removing a XhoI/XhoI fragment containing the complete SV40neo cassette. The vector pLXPCMTV was digested with the restriction enzyme XhoI yielding a 2266 bp and a 5544 bp fragment.

10 The digestion mixture was purified on a 0.8% agarose gel and the 5544 bp fragment band was excised and the DNA eluted using the Qiaquick protocol (Qiagen).

15 20 ng of the 5544 bp backbone was religated for 14 h at 16°C using T4 ligase (New England BioLabs). The ligase was inactivated at 65°C for 20 min and the DNA butanol precipitated with 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into DH10B bacteria (Gibco). Ampicillin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes SacII, EcoRI, ScaI and SpeI. The final correct intermediate plasmid was designated pLPCMTV.

20 25 The plasmid pTEJ-8 was digested with the restriction enzymes HindIII and NheI. The digestion mixture was purified on a 0.8% agarose gel. The 1586 bp fragment band was excised and the DNA eluted using the Qiaquick protocol (Qiagen). Nucleotides were filled in with the Klenow enzyme (Promega) for 30 min at 30°C. After inactivation of the Klenow enzyme for 30 min at 70°C the 1590 bp fragment was purified by running on a 0.8% agarose gel, the DNA band was excised and the DNA eluted using the Qiaquick protocol (Qiagen).

The vector pLPCMTV was digested with the restriction enzyme PshAI and the digested DNA was dephosphorylated with alkaline phosphatase (Promega) for 60 min at 50°C. After inactivation of the phosphatase for 60 min at 65°C the DNA was purified by running on a 0.8% agarose gel, the DNA band was excised and the DNA eluted using the Qiaquick protocol (Qiagen).

10 100 ng of the pLPCMTV backbone and 100 ng of the HindIII/NheI fragment were mixed and ligated for 14 h at 16°C using T4 ligase (New England BioLabs). The ligase was inactivated at 65°C for 20 min and the DNA butanol precipitated with 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into DH10B bacteria (Gibco).  
15 Ampicillin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes StuI, AvrII, BglII and SacI. The final correct intermediate plasmid was designated pRC1psh.sub.

20 For cloning the ubiquitin promoter obtained from the plasmid pRC1psh.sub into the ProCon derived expression vector pLXPCEGFP.r, both plasmids were digested with the restriction enzymes SspI and BstEII yielding a 6044 bp backbone and 3103 bp fragment, respectively. The digestion mixtures were purified on a 0.8% agarose gel. The 6044 bp backbone fragment and the 3103 bp fragment bands were excised and the DNA eluted using the Qiaquick protocol (Qiagen).

25 100 ng of the pLXPCEGFP.r backbone and 75 ng of the 3103 bp fragment were mixed and ligated for 1 h at room temperature using T4 ligase (New England BioLabs). The ligase was inactivated at 65°C for 20 min and the

5 DNA butanol precipitated with 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into DH10B bacteria (Gibco). Ampicillin/Kanamycin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes StuI and AvrII and sequenced. The final correct plasmid was designated pRC1UbpshEGFP.

10 2. Production of retroviral particles containing the *egfp* gene and the ubiquitin promoter by using the ReCon expression vector pRC1UbpshEGFP

15 For transfection of packaging cell lines (PA317)  $5 \times 10^5$  cells were seeded into 6-well dishes with a diameter of 35 mm. At the day of transfection 10  $\mu$ g of pRC1UbpshEGFP was transfected using the calcium-phosphate protocol Cellfect Kit (Pharmacia) according to the manufacturer's instructions.

20 18 h post transfection the medium was changed and 24 h post transfection the medium containing retroviral particles was removed and used for infection of target cells. 48 h post infection the ubiquitin/EGFP transfer was tested by FACS analysis of the target cells. New medium was added to the transfected packaging cells containing G418-Geneticin to select for stable transfected cell populations.

25 3. Infection of target cells with retroviral particles resultin in *egfp* gene expression regulated by the ubiqitin promoter after reverse transcription

For infection of target cells (NIH/3T3)  $5 \times 10^5$  cells in 10 ml medium were seeded in culture dishes with a diameter of 10 cm. At the day of infection,

2 ml of the supernatant containing vector virus (see above item 2.) and 2 µl Polybrene (final concentration 8 µg/ml) were added to the cells and  
5 incubated. After 6 hours 8 ml of culture medium was added and 24 h later the EGFP expression tested by FACS analysis. New medium containing G418-Geneticin was added to the infected cells to select for stable infected cells.

10 VI. ReCon expression vector pRC2UbpacEGFP

15 1. Construction of the ReCon expression vector pRC2UbpacEGFP containing the inverse *egfp* gene within the 3'LTR and the inverse ubiquitin promoter between the R and U5 region of the 5'LTR

15 The vector pRC2pacEGFP was constructed by introducing a unique PacI restriction site between the R and U5 region within the 5'LTR of the expression vector pLXPCEGFP.r.

20 The PacI restriction site was introduced by using the PCR method. For the first PCR reaction (PCR 1) the left hand primer (5'-GGCGACACGGAAATGTTGAA-3') was specific to the U3 region and the right hand primer (5'-  
25 GCGGGTTAATTAAATCGGATGCAAACAGCAAGAG-3') was specific to the beginning of the U5 region also creating the new PacI restriction site (underlined). The PCR resulted in a 936 bp fragment. For the second PCR reaction (PCR 2) the left hand primer (5'-  
CATCCTTAATTAAAGAACATCGTGGTCTCGCTGTT-3') was specific to the

beginning of the U5 region also creating the new PacI restriction site and the right hand primer (5'-GCCTGGTTGCTGACTAATTG-3') was specific to the end of the SV40ori. The PCR resulted in a 1095 bp fragment. The fragments from both PCR reactions were purified on a 0.8% agarose gel, the DNA bands were excised and DNA eluted using the Qiaquick protocol (Qiagen).

The vector pLXPCEGFP.r was digested with the restriction enzymes BamHI and SspI, the fragments from PCR 1 were digested with the restriction enzymes PacI and SspI, and the fragment from PCR 2 was digested with the restriction enzymes PacI and BamHI. The digestion mixtures were purified by running a 0.8% agarose gel, the DNA bands were excised and DNA eluted using the Qiaquick protocol (Qiagen).

25 ng of the pLXPCEGFP.r backbone, 100 ng of the PacI/SspI fragment of PCR 1 and 75 ng of the BamHI/ PacI fragment of PCR 2 were mixed. For ligation the temperature was increased for 1°C per hour from 10°C to 21°C and then incubated for 5 hours at 22°C using T4 ligase (New England BioLabs). The ligase was inactivated at 65°C for 20 min and the DNA transfected into DH5 $\alpha$  bacteria (Gibco) using the CaCl<sub>2</sub> method. Ampicillin/Kanamycin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes XmnI/StuI and XmnI/PacI and sequenced. The final correct intermediate plasmid was designated pRC2pacEGFP.

The ReCon expression vector pRC2UbpacEGFP was constructed by ligation of the fragment containing the ubiquitin promoter obtained from plasmid

pTEJ-8(Johansen et al. (1990) FEBS Lett. 267: 289-294) with the pRC2pacEGFP backbone.

5

The vector pRC2pacEGFP was digested with the restriction enzyme PacI linearising the vector, and the plasmid pTEJ-8 was digested with the restriction enzymes HindIII and NheI yielding a 1586 bp fragment. The digestion mixtures were purified by running a 0.8% agarose gel, the DNA bands were excised and DNA eluted using the Qiaquick protocol (Qiagen).

10 For blunt end ligation the overhanging nucleotide ends of the pRC2pacEGFP backbone were cut off with T4 polymerase (New England BioLabs) for 20 min at 12°C. After inactivation of the T4 polymerase for 10 min at 75°C the DNA was purified by running on a 0.8% agarose gel, the DNA band was excised and DNA eluted using the Qiaquick protocol (Qiagen). Finally, the purified DNA was dephosphorylated for 60 min at 50°C using the alkaline phosphatase (Promega), and the alkaline phosphatase inactivated for 60 min at 65°C.

15

20 The 1586 bp HindIII/NheI fragment was treated with the Klenow enzyme (New England BioLabs) to fill in nucleotides for blunt end ligation for 30 min at 30°C. After inactivation of the Klenow enzyme for 30 min at 70°C the DNA was purified by running on a 0.8% agarose gel, the DNA band was excised and DNA eluted using the Qiaquick protocol (Qiagen).

25

275 ng of the pRC2pacEGFP backbone and 75 ng of the 1590 bp HindIII/NheI fragment were mixed and ligated for 14 h at 16°C using T4 ligase (New England BioLabs). The ligase was inactivated at 65°C for

30

20 min and the DNA butanol precipitated with 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into 5 DH10B bacteria (Gibco). Ampicillin/Kanamycin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes StuI, XhoI and AvrII and sequenced. The final correct plasmid was designated pRC2UbpacEGFP.

10 2. Production of retroviral particles containing the *egfp* gene and the ubiquitin promoter by using the ReCon expression vector pRC2UbpacEGFP.

15 For transfection of packaging cell lines (PA317)  $5 \times 10^5$  cells were seeded into 6-well dishes with a diameter of 35 mm. At the day of transfection 10  $\mu\text{g}$  of pRC2UbpacEGFP was transfected using the calcium-phosphate protocol Cellfect Kit (Pharmacia) according to the manufacturer's instructions.

20 18 h post transfection the medium was changed, and 24 h post transfection the medium containing retroviral particles was removed and used for infection of target cells. 48 h post infection the ubiquitin/EGFP transfer was tested by FACS analysis of the target cells. New medium containing G418-Geneticin was added to the transfected packaging cells to select for stable transfected cell populations.

3. Infection of target cells with retroviral particles resulting in *egfp* gene expression regulated by the ubiquitin promoter after reverse transcription

For infection of target cells (NIH/3T3)  $5 \times 10^5$  cells in 10 ml medium were seeded in culture dishes with a diameter of 10 cm. At the day of infection, 2 ml of the supernatant containing recombinant retroviral particles (see above item 2) and 2  $\mu$ l Polybrene (final concentration 8  $\mu$ g/ml) were added to the cells and incubated. After 6 hours, 8 ml of culture medium was added and 24 h later the EGFP expression tested by FACS analysis. The cells were diluted 1:50, 1:100 and 1:200 in culture medium and seeded in culture dishes. 12 h later new medium containing G418-Geneticin was added to select for infected cell clones.

## VII. Recon expression vector pRC2UbpacpmEGFP

1. Construction of the ReCon expression vector pRC2UbpacpmEGFP containing the inverse *egfp* gene within the 3'LTR and the inverse ubiquitin promoter as well as an additional unique PmeI restriction site for easier exchange of promoters between the R and U5 region within the 5'LTR

The vector pRC2pacpmEGFP was constructed by introducing a unique PmeI restriction site between the R and U5 region of the 5'LTR of the vector pRC2pacEGFP.

The PmeI restriction site was introduced by using the PCR method. For the first PCR reaction (PCR 1) the left hand primer (5'-GGCGACACGGAAATGTTGAA') was specific to the U3 region and the right hand primer (5'-  
5 GAGCTTGTTTAAACCCAAGGAACAGCGAGACCAC-3') was specific to the center of the U5 region also creating the new PmeI restriction site (underlined). The PCR resulted in a 970 bp fragment. For the second PCR  
10 reaction (PCR 2) the left hand primer (5'-GAGCTTGTTTAAACCCCTGGGAGGGTCTCCTCTG-3') was specific to the center of the U5 region also creating the new PmeI restriction site, and the right hand primer (5'-GCCTGGTTGCTGACTAATTG-) was specific to the end of the SV40ori. The PCR resulted in a 1078 bp fragment. The fragments of both PCR reactions were purified on a 0.8% agarose gel, the DNA bands were excised and DNA eluted using the Qiaquick protocol (Qiagen).

20 The vector pRC2pacEGFP was digested with the restriction enzymes BamHI and SspI resulting in a 5711 bp fragment, the fragment from PCR 1 was digested with the restriction enzymes PmeI and SspI and the fragment from PCR 2 was digested with the restriction enzymes PmeI and BamHI. The digestion mixtures were purified by running a 0.8% agarose gel, the DNA bands were excised and DNA eluted using the Qiaquick protocol (Qiagen).

25 25 ng of the pRC2pacEGFP backbone, 100 ng of the PmeI/SspI fragment of PCR 1 and 75 ng of the BamHI/ PmeI fragment of PCR 2 were mixed. For ligation the temperature was increased for 1°C per hour from 10°C to 21°C and then incubated for 5 hours at 22°C using T4 ligase (New England

BioLabs). The ligase was inactivated at 65°C for 20 min and the DNA transfected into DH5 $\alpha$  bacteria (Gibco) using the CaCl<sub>2</sub> method. Ampicillin/Kanamycin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes XmuI/StuI and XmuI/PmeI and sequenced. The final correct intermediate plasmid was designated pRC2pacpmeEGFP.

The ReCon expression vector pRC2UbpacpmeEGFP was constructed by ligation of the fragment containing the ubiquitin promoter obtained by the PCR method from pTEJ-8 (Johansen et al. (1990) FEBS Lett. 267: 289-294) with the pRC2pacpmeEGFP backbone.

For the PCR reaction the left hand primer (5'-GAGCCTTGTAAACGAGCTCGCGAAAGCTAGC-3') was specific to the beginning of the ubiquitin promoter gene also creating a PmeI restriction site (underlined) and the right hand primer (5'-GC GGTTAATTAACGTCGACCTGCAGCCAAGCT-3') was specific to the end of the ubiquitin promoter gene also creating a PacI restriction site (underlined). PCR resulted in a 1647 bp fragment. The fragment was purified on a 0.8% agarose gel, the DNA band was excised and DNA eluted using the Qiaquick protocol (Qiagen). The PCR fragment was digested with the restriction enzymes PacI and PmeI yielding a 1628 bp fragment. The digestion mixture was purified on a 0.8% agarose gel, the DNA band was excised and DNA eluted using the Qiaquick protocol (Qiagen).

The pRC2pacpmeEGFP backbone was digested with the restriction enzymes PacI and PmeI yielding a 7549 bp fragment. The digestion mixture

was purified on a 0.8% agarose gel, the DNA band was excised and DNA eluted using the Qiaquick protocol (Qiagen).

5

25 ng of the pRC2pacpmeEGFP backbone and 100 ng of the PacI/PmeI fragment were mixed and ligated for 14 h at 16°C using T4 ligase (New England Biolabs). The ligase was inactivated at 65°C for 20 min and the DNA butanol precipitated with 10 fold volume of butanol. The precipitated DNA was resuspended in water and electroporated into DH10B bacteria (Gibco). Ampicillin/Kanamycin resistant colonies were selected, DNA prepared and test digested with the restriction enzymes StuI, HindIII and AvrII and sequenced. The final correct plasmid was designated pRC2UbpacpmeEGFP.

10

15 2. Production of retroviral particles containing the *egfp* gene and the ubiquitin promoter by using the ReCon expression vector pRC2UbpacpmeEGFP

20

For transfection of packaging cell lines (PA317) 5x10<sup>5</sup> cells were seeded into 6-well dishes with a diameter of 35 mm. At the day of transfection 10 µg of pRC2UbpacpmeEGFP was transfected using the calcium-phosphate protocol Cellfect Kit (Pharmacia) according to the manufacturer's instructions.

25

18 h post transfection the medium was changed, and 24 h post transfection the medium containing retroviral particles was removed and used for infection of target cells. 48 h post infection the ubiquitin/EGFP transfer was tested by FACS analysis of target cells. New medium containing G418-

30

Geneticin was added to the transfected packaging cells to select for stable transfected cell populations.

5

**3. Infection of target cells with retroviral particles resulting in the *egfp* gene expression regulated by the ubiquitin promoter after reverse transcription**

10

For infection of target cells (NIH/3T3)  $5 \times 10^5$  cells in 10 ml medium were seeded in culture dishes with a diameter of 10 cm. At the day of infection, 2 ml of the supernatant containing recombinant retroviral particles (see above item 2) and 2  $\mu$ l Polybrene (final concentration 8  $\mu$ g/ml) were added to the cells and incubated. After 6 hours, 8 ml of culture medium was added and 24 h later the EGFP expression tested by FACS analysis. Cells were diluted 1:50, 1:100 and 1:200 in culture medium and seeded in culture dishes. 12 h later medium containing G418-Geneticin was added to the infected cells to select for stable infected cell clones.

15

20

**C l a i m s**

- 5        1. A retroviral vector comprising one or more promoters inserted in antisense orientation within the 5' LTR region and one or more coding sequences inserted in antisense orientation within the 3' LTR region, both, the promoter as well as the coding sequence, inserted in such a way as to ensure that the promoter and the coding sequence  
10      become duplicated during the process of reverse transcription in a target cell and appear in the 3' as well as in the 5' LTR region of the resulting provirus in a fashion where the promoter is located upstream of the coding sequence allowing it to drive gene expression.
- 15      2. The retroviral vector according to claim 1, wherein said promoter is inserted within the U5 region of the 5' LTR.
3.        3. The retroviral vector according to claim 1 or 2, wherein said coding sequence is inserted within the U3 region of the 3' LTR.  
20
4.        4. The retroviral vector according to any of the preceding claims, wherein said coding sequence comprises heterologous DNA.
- 25      5. The retroviral vector according to claim 4, wherein said coding sequence is selected from one or more elements of the group consisting of marker genes, therapeutic genes, antiviral genes, antitumour genes, cytokine genes and/or toxin genes.
- 30      6. The retroviral vector according to any of the preceding claims, wherein said promoter is a strong, constitutive promoter.

7. The retroviral vector according to any of the preceding claims, wherein said retroviral vector is replication-defective.
- 5
8. The retroviral vector according to any of the preceding claims, wherein said retroviral vector is based on a vector of the pLXSN family.
- 10
9. The retroviral vector according to any of the preceding claims, wherein said retroviral vector is based on a promoter conversion vector.
- 15
10. A recombinant retroviral vector system comprising a retroviral vector according to any of the preceding claims 1-9 as a first component, and a packaging cell line harbouring at least one retroviral and/or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged.
- 20
11. A retroviral particle produced by transfecting a packaging cell line of a retroviral vector system according to claim 10 with the retroviral vector according to claim 10.
- 25
12. A retroviral provirus produced by infection of target cells with a recombinant retroviral particle according to claim 11.
13. mRNA of a retroviral provirus according to claim 12.
- 30
14. RNA of a retroviral vector according to any of the preceding claims 1-9.

15. A host cell infected with a retroviral particle according to claim  
11.

5

16. A pharmaceutical composition containing a therapeutically effective amount of a recombinant retroviral particle according to claim 11 and/or a recombinant retroviral vector system according to claim 10.

10


17. A method for introducing homologous and/or heterologous nucleotide sequences into target cells comprising infecting the target cells with recombinant retroviral particles according to claim 11.

15

18. Use of a recombinant retroviral vector according to any of the preceding claims 1-9 and/or of a recombinant retroviral vector system according to claim 10 and/or of a retroviral particle according to claim 11 for producing a pharmaceutical composition for gene therapy.

20

1/1  
ReCon Vector



**Figure 1**

# INTERNATIONAL SEARCH REPORT

Inte...onal Application No  
PCT/EP 99/00002

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC 6 C12N15/86 C12N5/10 C12N7/01 A61K48/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 6 C12N A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 07748 A (GSF FORSCHUNGSZENTRUM UMWELT ;GUENZBURG WALTER HENRY (DE); SALLER) 14 March 1996 cited in the application see the whole document	1-18
Y	WO 89 11539 A (SLOAN KETTERING INST CANCER) 30 November 1989 see the whole document, especially Fig. 4	1-18
A	WO 96 28563 A (BAVARIAN NORDIC ;GSF FORSCHUNGSZENTRUM UMWELT (DE); GUENZBURG WALT) 19 September 1996 see the whole document	1-18
<input type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		
<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search		Date of mailing of the international search report
3 June 1999		10/06/1999
Name and mailing address of the ISA		Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Mandl, B

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/00002

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

**Remark:** Although claims 17, as far as it refers to an in vivo application, is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2.  Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3.  Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte	onal Application No
PCT/EP 99/00002	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9607748	A 14-03-1996	AU 688590	B	12-03-1998
		AU 3520195	A	27-03-1996
		BR 9508664	A	06-01-1998
		CA 2198210	A	14-03-1996
		CN 1159210	A	10-09-1997
		EP 0779929	A	25-06-1997
		FI 970892	A	28-02-1997
		HU 76974	A	28-01-1998
		JP 10507628	T	28-07-1998
		NO 970902	A	24-04-1997
		NZ 292897	A	26-08-1998
		PL 319033	A	21-07-1997
WO 8911539	A 30-11-1989	AT 142268	T	15-09-1996
		AU 631554	B	03-12-1992
		AU 3740489	A	12-12-1989
		CA 1335798	A	06-06-1995
		DE 68927089	D	10-10-1996
		DE 68927089	T	03-04-1997
		DK 13290	A	16-03-1990
		EP 0371119	A	06-06-1990
		JP 2504344	T	13-12-1990
		US 5658775	A	19-08-1997
WO 9628563	A 19-09-1996	AU 5103996	A	02-10-1996
		EP 0817858	A	14-01-1998
		JP 11503305	T	26-03-1999